We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+3.9%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$270M
AUM Growth
-$974K
Cap. Flow
+$3.47M
Cap. Flow %
1.29%
Top 10 Hldgs %
48.55%
Holding
70
New
8
Increased
19
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$7.67M
2
AMGN icon
Amgen
AMGN
+$7.52M
3
INSM icon
Insmed
INSM
+$6.87M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.37M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$8.83M
2
AERI
Aerie Pharmaceuticals
AERI
+$7.18M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$5.83M
4
WVE icon
Wave Life Sciences
WVE
+$5.63M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$5.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$185B
$21.4M 7.92%
316,284
+38,000
+14% +$2.5M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$139B
$15.6M 5.78%
85,022
+33,900
+66% +$5.93M
NBIX icon
3
Neurocrine Biosciences
NBIX
$15.8B
$13.2M 4.91%
156,800
+53,200
+51% +$4.37M
CELG
4
DELISTED
Celgene Corp
CELG
$13.2M 4.88%
142,522
-93,000
-39% -$8.83M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$12.9M 4.79%
98,641
+25,000
+34% +$3.22M
AMGN icon
6
Amgen
AMGN
$236B
$12.2M 4.51%
66,000
+42,000
+175% +$7.52M
PTCT icon
7
PTC Therapeutics
PTCT
$5.99B
$11.6M 4.32%
259,000
+18,507
+8% +$731K
STML
8
DELISTED
Stemline Therapeutics, Inc.
STML
$11.4M 4.23%
744,245
-52,000
-7% -$752K
BIIB icon
9
Biogen
BIIB
$32.7B
$9.98M 3.7%
42,700
+33,200
+349% +$7.67M
EXEL icon
10
Exelixis
EXEL
$13.7B
$9.48M 3.52%
443,534
+200,000
+82% +$4.19M
ILMN icon
11
Illumina
ILMN
$34.3B
$9.24M 3.43%
25,803
– –
INSM icon
12
Insmed
INSM
$26.5B
$9.11M 3.38%
356,600
+246,600
+224% +$6.87M
HALO icon
13
Halozyme
HALO
$12.1B
$8.16M 3.03%
475,633
– –
REGN icon
14
Regeneron Pharmaceuticals
REGN
$83.1B
$7.3M 2.71%
23,330
-8,300
-26% -$2.76M
INCY icon
15
Incyte
INCY
$25.9B
$6.71M 2.49%
79,000
-22,500
-22% -$1.81M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$6.22M 2.31%
33,996
– –
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$12.6B
$5.51M 2.04%
64,284
– –
IONS icon
18
Ionis Pharmaceuticals
IONS
$10.4B
$5.32M 1.97%
82,781
+35,000
+73% +$2.47M
GTHX
19
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.47M 1.66%
146,000
+47,518
+48% +$1M
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$4.21M 1.56%
60,900
– –
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$4.17M 1.54%
187,599
-25,462
-12% -$597K
SRPT icon
22
Sarepta Therapeutics
SRPT
$2.28B
$3.96M 1.47%
26,100
+12,300
+89% +$1.49M
HZNP
23
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.08M 1.14%
128,000
– –
ABMD
24
DELISTED
Abiomed Inc
ABMD
$3.05M 1.13%
11,700
– –
ASND icon
25
Ascendis Pharma A/S
ASND
$16.4B
$2.97M 1.1%
25,800
+12,000
+87% +$1.44M
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2019 Portfolio in Review

As of Q2 2019, International Biotechnology Trust held 70 positions worth $270M, down 0.36% from $271M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

International Biotechnology Trust's Q2 2019 filing shows 8 new, 19 increased, 15 reduced and 6 closed positions. Its largest new stake was uniQure: 27,500 shares worth $2.15M. The largest sale was Celgene Corp, an estimated $8.83M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q2 2019 buy was uniQure: 27,500 shares worth $2.15M.
  • International Biotechnology Trust added most to Biogen in Q2 2019, an estimated $7.67M increase.
  • International Biotechnology Trust's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $8.83M.
  • International Biotechnology Trust fully exited Aerie Pharmaceuticals in Q2 2019, selling an estimated $7.18M.
  • International Biotechnology Trust's ten largest holdings make up 49% of its $270M portfolio in Q2 2019.
  • International Biotechnology Trust opened 8 new positions and closed 6 in Q2 2019.
  • International Biotechnology Trust's portfolio value fell 0.36% quarter-over-quarter to $270M.

Based on International Biotechnology Trust's 13F filing for Q2 2019, filed 14 Aug 2019.